PHARMING GRP SP. ADRS (PHG) - Total Assets
Based on the latest financial reports, PHARMING GRP SP. ADRS (PHG) holds total assets worth €499.96 Million EUR (≈ $584.51 Million USD) as of December 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Explore cash flow to debt ratio of PHARMING GRP SP. ADRS to assess how comfortably operating cash covers total debt obligations.
PHARMING GRP SP. ADRS - Total Assets Trend (2021–2025)
This chart illustrates how PHARMING GRP SP. ADRS's total assets have evolved over time, based on quarterly financial data. See PHG net assets for net asset value and shareholders' equity analysis.
PHARMING GRP SP. ADRS - Asset Composition Analysis
Current Asset Composition (December 2025)
PHARMING GRP SP. ADRS's total assets of €499.96 Million consist of 59.9% current assets and 40.1% non-current assets.
| Asset Category | Amount (EUR) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | €0.00 | 29.1% |
| Accounts Receivable | €41.77 Million | 8.4% |
| Inventory | €64.90 Million | 13.0% |
| Property, Plant & Equipment | €0.00 | 0.0% |
| Intangible Assets | €132.22 Million | 26.5% |
| Goodwill | €3.32 Million | 0.7% |
Asset Composition Trend (2021–2025)
This chart illustrates how PHARMING GRP SP. ADRS's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see PHARMING GRP SP. ADRS market capitalisation.
Key Asset Composition Facts
- Current vs. Non-Current Assets: PHARMING GRP SP. ADRS's current assets represent 59.9% of total assets in 2025, a decrease from 62.8% in 2021.
- Cash Position: Cash and equivalents constituted 29.1% of total assets in 2025, down from 48.3% in 2021.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 26.0% of total assets, an increase from 21.0% in 2021.
- Asset Diversification: The largest asset category is intangible assets at 26.5% of total assets.
PHARMING GRP SP. ADRS Competitors by Total Assets
Key competitors of PHARMING GRP SP. ADRS based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Halozyme Therapeutics Inc
NASDAQ:HALO
|
USA | $2.22 Billion |
|
Soleno Therapeutics Inc
NASDAQ:SLNO
|
USA | $608.39 Million |
|
Neuren Pharmaceuticals Ltd
AU:NEU
|
Australia | AU$331.25 Million |
|
Genfit S.A.
PA:GNFT
|
France | €157.93 Million |
|
Hyundai Bioscience Co. Ltd
KQ:048410
|
Korea | ₩129.10 Billion |
|
Altimmune Inc
NASDAQ:ALT
|
USA | $279.93 Million |
|
Clarity Pharmaceuticals Ltd
AU:CU6
|
Australia | AU$255.67 Million |
|
Jiangsu GDK Biotechnology Co Ltd
SHG:688670
|
China | CN¥1.48 Billion |
PHARMING GRP SP. ADRS - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 2.59 | 3.77 | 3.53 |
| Quick Ratio | 2.03 | 3.02 | 2.76 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | €183.68 Million | €204.64 Million | €202.35 Million |
PHARMING GRP SP. ADRS - Advanced Valuation Insights
This section examines the relationship between PHARMING GRP SP. ADRS's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 3.20 |
| Latest Market Cap to Assets Ratio | 1.53 |
| Asset Growth Rate (YoY) | 25.0% |
| Total Assets | €499.96 Million |
| Market Capitalization | $762.66 Million USD |
Valuation Analysis
Above Book Valuation: The market values PHARMING GRP SP. ADRS's assets above their book value (1.53x), reflecting positive investor sentiment about the company's future prospects.
Rapid Asset Growth: PHARMING GRP SP. ADRS's assets grew by 25.0% over the past year, indicating significant expansion of the company's resource base.
Annual Total Assets for PHARMING GRP SP. ADRS (2021–2025)
The table below shows the annual total assets of PHARMING GRP SP. ADRS from 2021 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | €499.96 Million ≈ $584.51 Million |
+25.00% |
| 2024-12-31 | €399.99 Million ≈ $467.62 Million |
-13.58% |
| 2023-12-31 | €462.85 Million ≈ $541.12 Million |
+8.70% |
| 2022-12-31 | €425.80 Million ≈ $497.80 Million |
+7.17% |
| 2021-12-31 | €397.31 Million ≈ $464.50 Million |
-- |
About PHARMING GRP SP. ADRS
Pharming Group N.V., a biopharmaceutical company, develops and commercializes protein replacement therapies and precision medicines for the treatment of rare diseases in the United States, Europe, and internationally. The company's lead product is RUCONEST, a recombinant C1 esterase inhibitor for the treatment of acute attacks in adult and adolescent patients with acute hereditary angioedema (HAE… Read more